Tango Therapeutics, INC 8-K filings

Tango Therapeutics has filed an update to its at-the-market offering program, increasing the potential aggregate offering price to $400 million and terminating a prior supplement.

Tango Therapeutics announced strong Phase 1/2 data for vopimetostat in pancreatic cancer, positioning it for Phase 3 development, and reported a cash position of $1.0 billion as of June 30, 2026.

Tango Therapeutics, Inc. has filed an 8-K/A to amend its previous filing, detailing the separation agreement for Executive Chair Dr. Barbara Weber, effective August 3, 2026.

Tango Therapeutics reports the departure of Executive Chair Dr. Barbara Weber, effective August 3, 2026, with standard separation terms outlined.

Tango Therapeutics announced a public offering of common stock and pre-funded warrants expected to raise approximately $566.5 million.

Tango Therapeutics announced highly encouraging initial safety and efficacy data from its Phase 1/2 combination trial of vopimetostat with RAS(ON) inhibitors in pancreatic cancer patients.

Tango Therapeutics shareholders elected two directors, ratified its auditor, and approved executive compensation at the 2026 annual meeting.

Tango Therapeutics announced first quarter 2026 financial results, highlighting a strong cash position and providing updates on its clinical pipeline, including anticipated data readouts for vopimetostat.

Tango Therapeutics has finalized a separation agreement with former CFO Daniella Beckman, effective May 1, 2026.

Tango Therapeutics announced leadership changes, appointing Matthew Gall as CFO and adding executives to support late-stage development of vopimetostat.

Tango Therapeutics announced its Q4 and full-year 2025 financial results, highlighted by a strong cash position into 2028 and significant progress in its vopimetostat clinical programs.

Tango Therapeutics announced the retirement of its founding CEO, Barbara Weber, M.D., and the appointment of board member Malte Peters, M.D., as her successor, alongside an update on its cash position and 2026 clinical milestones.

Tango Therapeutics, Inc. announced the appointment of Sung H. Lee, an experienced biopharmaceutical finance leader, to its Board of Directors, expanding the board to eight members.

Tango Therapeutics has established a new 'at-the-market' equity offering program for up to $100 million with Leerink Partners LLC, while terminating its previous program with Jefferies LLC.

Tango Therapeutics announced strong third-quarter 2025 financial results, including a net income of $15.9 million, and extended its cash runway into 2028 following a $225 million financing.

Tango Therapeutics, Inc. announced a registered direct offering and a concurrent private placement, raising approximately $212 million to fund its pipeline and operations into 2028.

Tango Therapeutics disclosed preliminary cash of $152.8M and positive Phase 1/2 clinical trial results for vopimetostat, showing durable tumor control and favorable tolerability across multiple cancer types.

Douglas Barry has resigned from his roles as Chief Legal and Compliance Officer and Corporate Secretary of Tango Therapeutics, effective September 12, 2025.

Tango Therapeutics reported its second quarter 2025 financial results, highlighting progress in its clinical pipeline and a reduced research collaboration term with Gilead.

Tango Therapeutics, Inc. announced that its stockholders approved an amendment to increase the authorized common stock from 200 million to 400 million shares, alongside other key proposals at its 2025 annual meeting.

Tango Therapeutics announced its first quarter 2025 financial results, highlighting progress in its clinical programs and extending its cash runway into Q1 2027 through cost reductions.

Tango Therapeutics announces promising clinical data for its lead PRMT5 program, TNG462, along with FDA clearances and collaborations, while reporting a solid cash position to fund operations into Q3 2026.

Tango Therapeutics reports a strong cash position of $257.9 million as of December 31, 2024, and provides updates on its clinical programs, including TNG462, TNG456, and TNG260.

Tango Therapeutics is prioritizing its TNG462 program after promising clinical trial results and plans to advance a new brain-penetrant inhibitor, TNG456, into clinical trials.

Tango Therapeutics announced its second quarter 2024 financial results, highlighting progress in clinical trials and a strong cash position.

Tango Therapeutics held its annual meeting, approving an amendment to its charter to limit officer liability and electing three Class III directors.

Tango Therapeutics has discontinued its TNG348 program due to liver toxicity observed in patients during a Phase 1/2 clinical trial, shifting focus to its PRMT5 and CoREST programs.

Tango Therapeutics announced its first quarter 2024 financial results, highlighted by a strong cash position and progress in clinical trials for its precision oncology programs.

Tango Therapeutics announced positive clinical advancements across its four oncology programs and a robust cash position extending into late 2026.

Tango Therapeutics announced a cash balance of $337 million as of December 31, 2023, and expects to fund operations into late 2026 following a recent at-the-market offering.